Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Earnings

Cypherpunk's Zcash-fuelled profit masks open question over Leap's colorectal cancer drug

A large non-cash gain lifted the former Leap Therapeutics to a $306M quarterly profit, while the fate of sirexatamab now hinges on finding outside backing.

16 Nov 2026 · Cypherpunk Technologies Inc. CYPH · Company news

Cypherpunk Technologies, the Nasdaq-listed company that was formerly Leap Therapeutics, posted third-quarter 2026 net income of $306M on 16 November. The company puts the result down to a sizeable non-cash derivative gain rather than to trading in its drug business.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Cypherpunk Technologies Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More EarningsAll →